What's Happening?
Researchers have identified a hormone called ghrelin and its antagonist LEAP2 as potential indicators of anorexia nervosa relapse. The study, presented at the Federation of European Neuroscience Societies Forum 2026, involved 30 women undergoing treatment
for anorexia. Findings suggest that higher levels of LEAP2 correlate with increased impulsivity and relapse risk. This discovery could lead to new therapeutic strategies and the development of blood tests to predict relapse in anorexia patients.
Why It's Important?
Anorexia nervosa is a severe eating disorder with high relapse rates, posing significant challenges for treatment. The identification of LEAP2 as a biomarker for relapse offers a promising avenue for early intervention, potentially improving patient outcomes. By enabling healthcare providers to tailor treatments based on individual relapse risk, this research could enhance the effectiveness of anorexia therapies and reduce the disorder's long-term impact.
